Incanthera PLC Notice of AGM and Posting of Accounts (0298Y)
September 02 2022 - 2:01AM
UK Regulatory
TIDMINC
RNS Number : 0298Y
Incanthera PLC
02 September 2022
2 September 2022
Incanthera plc
("Incanthera" or the "Company")
Notice of Annual General Meeting 2022 and Posting of Annual
Report and Accounts
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in oncology and dermatology,
confirms that the Annual Report and Accounts for the year ended 31
March 2022, and the Notice of Annual General Meeting ("AGM") with
accompanying Form of Proxy has been posted to shareholders
today.
These documents are also available, in electronic form, for
download on the Company's website: www.incanthera.com
Incanthera's AGM will be held at 11:00 a.m. on Tuesday, 27
September 2022 at the offices of Gateley Plc, Ship Canal House, 98
King Street, Manchester, M2 4WU.
The Meeting will focus on the formal business of the meeting
only.
In order to ensure that all shareholders are able to follow the
proceedings of the AGM, the Company will provide access online
through the Investor Meet Company platform. However, shareholders
will not be able to vote online during the Meeting and are
therefore urged to submit their votes via proxy as early as
possible, electronically or by post.
Shareholders are also invited to submit written questions for
the Board to consider. Questions can be pre submitted in advance of
the AGM via the Investor Meet Company Platform up to 9.00am on 26
September 2022, being the day before the AGM, or via the Investor
Meet Platform at any time during the AGM itself.
The Board will respond to key questions during the meeting and
will provide such answers on its website thereafter.
Shareholders who wish to attend the AGM online should register
for the event in advance via the following link:
https://www.investormeetcompany.com/incanthera-plc/register-investor
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob
Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on
innovative technologies in dermatology and oncology. It seeks to
identify and develop innovative solutions to current clinical,
commercially relevant unmet needs, utilising new technology from
leading specialists and academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. The company is in
active discussions with Global partners for a potential licensing
deal for Sol.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in its
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
@incantheraplc
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUAVARUBUKRUR
(END) Dow Jones Newswires
September 02, 2022 02:01 ET (06:01 GMT)
Incanthera (AQSE:INC)
Historical Stock Chart
From Apr 2024 to May 2024
Incanthera (AQSE:INC)
Historical Stock Chart
From May 2023 to May 2024